Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Treatment Study for Patients with HER2-Expressing Cancers
To evaluate the maximal tolerated dose (MTD), optimal biological dose (OBD) or other recommended dose (RD), and overall safety and tolerability of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers.
In order to participate you must meet the following criteria:
- Have HER2-expressing cancer.
- Have an ECOG of 0 or 1.
- Have adequate renal function.
- Are at least 18 years of age.
This is a partial list of elgibility requirements.